peptide sciences glp-1 S 5mg GLP-1 therapies are booming -
Description
43% of Americans say they are overweight
This discovery led to the development of exenatide, the first GLP-1 receptor agonist approved for type 2 diabetes in 2005
Nat Rev Endocrinol 2015;11:57791
Neurogastroenterol Motil 2017;29
For comparison, in 2019, spending for traditional medications decreased by 5% while spending on specialty drugs grew by 11.5%
